Background: End-stage liver disease is a common cause of morbidity and mortality
worldwide, yet little is known about its symptomatology and impact on health-related quality …

Funding for the development of this Practice Guidance was provided by the American
Association for the Study of Liver Diseases. MV was supported by aAQ19 Patient-Centered …

Diagnosing and managing metabolic dysfunction-associated steatotic liver disease
(MASLD) remains a major challenge in primary care due to lack of agreement on diagnostic …

Background Opioid use is epidemic in cirrhosis, which could precipitate hepatic
encephalopathy (HE) potentially through gut dysbiosis and inflammation. Aim To define the …

Background: Symptom-focused trials are critically needed for patients with cirrhosis.
However, this work would benefit from standard processes and validated measures …

Background & Aims Non-alcoholic steatohepatitis (NASH) is known to have a negative
impact on patients' health-related quality of life (HRQoL), even before progression to …

Background Opioids are often prescribed for pain in cirrhosis and may increase the risk of
hepatic encephalopathy (HE). Aim To assess the association between opioids and HE in …

Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐
related quality of life and poor functional status. However, there is limited guidance on …

Abstract Purpose of Review The treatment of pain in patients with cirrhosis is complicated by
unpredictable hepatic drug metabolism and a higher risk of adverse drug reactions. We …

Background & Aims Despite increased risks for adverse effects in patients with cirrhosis, little
is known about opioid prescriptions for this population. We aimed to assess time trends in …